Jin Yang Pharmaceutical Co., Ltd.

KOSDAQ:A007370 Stock Report

Market Cap: ₩66.8b

Jin Yang Pharmaceutical Past Earnings Performance

Past criteria checks 5/6

Jin Yang Pharmaceutical has been growing earnings at an average annual rate of 36.5%, while the Pharmaceuticals industry saw earnings growing at 7.5% annually. Revenues have been growing at an average rate of 18.6% per year. Jin Yang Pharmaceutical's return on equity is 23.8%, and it has net margins of 25.3%.

Key information

36.5%

Earnings growth rate

37.3%

EPS growth rate

Pharmaceuticals Industry Growth11.3%
Revenue growth rate18.6%
Return on equity23.8%
Net Margin25.3%
Last Earnings Update30 Sep 2024

Recent past performance updates

Shareholders Shouldn’t Be Too Comfortable With Jin Yang Pharmaceutical's (KOSDAQ:007370) Strong Earnings

Nov 22
Shareholders Shouldn’t Be Too Comfortable With Jin Yang Pharmaceutical's (KOSDAQ:007370) Strong Earnings

Jin Yang Pharmaceutical's (KOSDAQ:007370) Problems Go Beyond Weak Profit

May 23
Jin Yang Pharmaceutical's (KOSDAQ:007370) Problems Go Beyond Weak Profit

Recent updates

Shareholders Shouldn’t Be Too Comfortable With Jin Yang Pharmaceutical's (KOSDAQ:007370) Strong Earnings

Nov 22
Shareholders Shouldn’t Be Too Comfortable With Jin Yang Pharmaceutical's (KOSDAQ:007370) Strong Earnings

Jin Yang Pharmaceutical Co., Ltd. (KOSDAQ:007370) Shares Fly 32% But Investors Aren't Buying For Growth

Aug 19
Jin Yang Pharmaceutical Co., Ltd. (KOSDAQ:007370) Shares Fly 32% But Investors Aren't Buying For Growth

These 4 Measures Indicate That Jin Yang Pharmaceutical (KOSDAQ:007370) Is Using Debt Reasonably Well

Aug 12
These 4 Measures Indicate That Jin Yang Pharmaceutical (KOSDAQ:007370) Is Using Debt Reasonably Well

Jin Yang Pharmaceutical's (KOSDAQ:007370) Problems Go Beyond Weak Profit

May 23
Jin Yang Pharmaceutical's (KOSDAQ:007370) Problems Go Beyond Weak Profit

A Look At The Intrinsic Value Of Jin Yang Pharmaceutical Co., Ltd. (KOSDAQ:007370)

Mar 22
A Look At The Intrinsic Value Of Jin Yang Pharmaceutical Co., Ltd. (KOSDAQ:007370)

Here's Why I Think Jin Yang Pharmaceutical (KOSDAQ:007370) Is An Interesting Stock

Mar 04
Here's Why I Think Jin Yang Pharmaceutical (KOSDAQ:007370) Is An Interesting Stock

These 4 Measures Indicate That Jin Yang Pharmaceutical (KOSDAQ:007370) Is Using Debt Safely

Feb 11
These 4 Measures Indicate That Jin Yang Pharmaceutical (KOSDAQ:007370) Is Using Debt Safely

Are Jin Yang Pharmaceutical Co., Ltd.'s (KOSDAQ:007370) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?

Jan 21
Are Jin Yang Pharmaceutical Co., Ltd.'s (KOSDAQ:007370) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?

Does Jin Yang Pharmaceutical's (KOSDAQ:007370) Share Price Gain of 49% Match Its Business Performance?

Jan 04
Does Jin Yang Pharmaceutical's (KOSDAQ:007370) Share Price Gain of 49% Match Its Business Performance?

We're Not So Sure You Should Rely on Jin Yang Pharmaceutical's (KOSDAQ:007370) Statutory Earnings

Dec 17
We're Not So Sure You Should Rely on Jin Yang Pharmaceutical's (KOSDAQ:007370) Statutory Earnings

Here's Why We Think Jin Yang Pharmaceutical (KOSDAQ:007370) Is Well Worth Watching

Nov 30
Here's Why We Think Jin Yang Pharmaceutical (KOSDAQ:007370) Is Well Worth Watching

Revenue & Expenses Breakdown

How Jin Yang Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

KOSDAQ:A007370 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24111,14928,13260,0810
30 Jun 24103,6019,80756,4990
31 Mar 2499,16811,76653,1480
31 Dec 2394,11112,65947,8510
30 Sep 2387,80612,95141,9460
30 Jun 2385,54615,21939,1010
31 Mar 2380,97313,35236,3200
31 Dec 2276,26412,30834,0310
30 Sep 2274,99112,23431,8020
30 Jun 2268,7828,12429,0940
31 Mar 2266,7468,83927,5580
31 Dec 2162,8399,53826,5830
30 Sep 2158,68011,01624,2120
30 Jun 2154,92710,27022,3090
31 Mar 2151,0997,30721,9590
31 Dec 2049,5255,22921,6470
30 Sep 2049,7862,46524,0190
30 Jun 2048,19792624,4310
31 Mar 2047,87971824,4130
31 Dec 1947,3511,64723,9450
30 Sep 1947,6911,35423,9430
30 Jun 1948,9032,04224,4600
31 Mar 1947,5772,11923,7500
31 Dec 1846,86393323,9910
30 Sep 1844,319-5,35328,8120
30 Jun 1843,858-5,34927,9670
31 Mar 1843,815-5,72428,2570
31 Dec 1743,450-5,76827,8540
30 Sep 1742,432-6,37229,1730
30 Jun 1740,902-7,05428,7850
31 Mar 1740,833-7,24228,1540
31 Dec 1636,132-9,09926,9860
30 Sep 1636,191-3,67421,0950
30 Jun 1635,729-3,53821,7240
31 Mar 1635,400-3,94822,5730
31 Dec 1540,149-1,00423,0740
30 Sep 1544,3883,05821,9230
30 Jun 1546,2463,31122,7780
31 Mar 1546,6904,09922,3900
31 Dec 1445,2374,01321,6360
30 Sep 1444,4284,33319,9240
30 Jun 1443,3795,50118,6670
31 Mar 1440,4584,72718,5190
31 Dec 1340,2354,19318,9490

Quality Earnings: A007370 has a high level of non-cash earnings.

Growing Profit Margin: A007370's current net profit margins (25.3%) are higher than last year (14.8%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: A007370's earnings have grown significantly by 36.5% per year over the past 5 years.

Accelerating Growth: A007370's earnings growth over the past year (117.2%) exceeds its 5-year average (36.5% per year).

Earnings vs Industry: A007370 earnings growth over the past year (117.2%) exceeded the Pharmaceuticals industry 22.3%.

Return on Equity

High ROE: A007370's Return on Equity (23.8%) is considered high.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 07:42
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Jin Yang Pharmaceutical Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution